Roivant Sciences (ROIV) Operating Leases (2021 - 2026)

Roivant Sciences has reported Operating Leases for 6 years, with the latest figure at $96.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 6.6% year-over-year to $96.3 million; the trailing twelve-month figure through Mar 2026 stood at $96.3 million (up 6.6% YoY), and the FY2026 full-year result was $96.3 million, up 6.6% from the prior year.
• Operating Leases for Q1 2026 stood at $96.3 million, down from $98.5 million in the prior quarter.
• The five-year high for Operating Leases was $98.5 million in Q4 2025, with the low at $45.0 million in Q1 2024.
• Historically, Operating Leases has averaged $66.4 million across 5 years, with a median of $54.9 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Leases retreated 17.06% — and 2025, when it jumped 100.64%.
• Roivant Sciences' Operating Leases stood at $54.9 million in 2022, then declined by 14.32% to $47.1 million in 2023, then surged by 92.27% to $90.5 million in 2024, then grew by 8.87% to $98.5 million in 2025, then slipped by 2.25% to $96.3 million in 2026.
• The last three Operating Leases figures came in at $96.3 million (Q1 2026), $98.5 million (Q4 2025), and $89.8 million (Q3 2025), per Business Quant data.